Literature DB >> 23538464

Serum visfatin levels do not increase in post-menopausal women with metabolic syndrome.

N Güdücü1, H İsçi, U Görmüş, A B Yiğiter, İ Dünder.   

Abstract

BACKGROUND: The aim of this study was to determine the serum visfatin levels in post-menopausal (PM) women with and without metabolic syndrome (MS) and to understand the correlation between serum visfatin levels and various other hormonal and metabolic parameters. MATERIALS-
METHODS: We conducted a prospective cross-sectional study including 17 PM women with MS and a control group of 51 PM women without MS. MS was defined according to the National Cholesterol Education Program Adult Treatment Panel III.
RESULTS: Women with MS had statistically significantly higher fasting blood glucose, HDL, triglycerides, insulin, homeostasis model assessment of insulin resistance, and SHBG levels when compared to women without MS. Estradiol, high sensitivity C-reactive protein, and free testosterone levels were higher in the MS group, but there was no statistically significant difference between the two groups. Visfatin levels did not differ between the two groups. There was no correlation between serum visfatin levels and other parameters.
CONCLUSIONS: There was no association between serum visfatin levels and MS in PM women. ©2013, Editrice Kurtis

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23538464     DOI: 10.1007/BF03346752

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

1.  Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women.

Authors:  Ji A Seo; Eun Suk Jang; Baek Gil Kim; Ohk Hyun Ryu; Hee Young Kim; Kye Won Lee; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Dong Seop Choi; Nan Hee Kim
Journal:  Diabetes Res Clin Pract       Date:  2007-09-27       Impact factor: 5.602

Review 2.  Adipose tissue: from lipid storage compartment to endocrine organ.

Authors:  Philipp E Scherer
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

3.  Changes in body composition in women over six years at midlife: ovarian and chronological aging.

Authors:  MaryFran Sowers; Huiyong Zheng; Kristin Tomey; Carrie Karvonen-Gutierrez; Mary Jannausch; Xizhao Li; Matheos Yosef; James Symons
Journal:  J Clin Endocrinol Metab       Date:  2006-12-27       Impact factor: 5.958

4.  Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort.

Authors:  Sherita Hill Golden; Ann Maguire; Jingzhong Ding; J R Crouse; Jane A Cauley; Howard Zacur; Moyses Szklo
Journal:  Am J Epidemiol       Date:  2002-03-01       Impact factor: 4.897

5.  Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study.

Authors:  Jee-Young Oh; Elizabeth Barrett-Connor; Nicole M Wedick; Deborah L Wingard
Journal:  Diabetes Care       Date:  2002-01       Impact factor: 19.112

6.  A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome.

Authors:  Micheline C Chu; Pippa Cosper; Gary S Nakhuda; Rogerio A Lobo
Journal:  Fertil Steril       Date:  2006-10-30       Impact factor: 7.329

Review 7.  Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.

Authors:  Eric L Ding; Yiqing Song; Vasanti S Malik; Simin Liu
Journal:  JAMA       Date:  2006-03-15       Impact factor: 56.272

8.  Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome.

Authors:  Cheng-Chieh Lin; Ming-May Lai; Tsai-Chung Li; Chia-Ing Li; Chiu-Shong Liu; Ching-Chu Chen; Ming-Tsang Wu
Journal:  Diabetes Res Clin Pract       Date:  2009-04-28       Impact factor: 5.602

9.  Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes.

Authors:  R MacLaren; W Cui; K Cianflone
Journal:  Diabetes Obes Metab       Date:  2007-07       Impact factor: 6.577

10.  Circulating visfatin level is correlated with inflammation, but not with insulin resistance.

Authors:  Kenji Oki; Kiminori Yamane; Nozomu Kamei; Hideki Nojima; Nobuoki Kohno
Journal:  Clin Endocrinol (Oxf)       Date:  2007-07-18       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.